Company / Cost of Revenue
Sarepta Therapeutics Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$25.5M
FY2025
5-year range
$25.5M / $25.5M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
#61 of 85
Health Care
What the data says
At $26M, Sarepta Therapeutics's cost of revenue ranks #25 of 85 in the Health Care sector.
Based on SEC 10-K filings.
$26M in FY2025.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#25 of 85 in Health CareTop 28% of 85This company $25.5M Sector average $2.0B
▼
-98.7% below sector average
Key checks
Key Insights
- Ranks #61 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.5M | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | $130.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026